Papzimias: A first-in-class FDA-approved gene therapy indicated for adult patients with recurrent respiratory papillomatosis (RRP), based on a proprietary adenovector technology platform. AdenoVerse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results